Intuitive revealed that it’s finished the acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates.

This marks the formal expansion of Intuitive’s direct operations in Europe, allowing the company to support customers in a more agile and integrated manner. It will bring minimally invasive care to more patients in Italy, Spain, Portugal, Malta, San Marino and associated territories.

“Today marks an important step in our commitment to expanding access to proven, safe and effective minimally invasive care to more patients across Europe,” said Intuitive CEO Dave Rosa. “Our direct presence means we are better positioned to meet the needs of our customers in these geographies as we drive forward our shared goals of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost of care.”

ab medica, Abex, and Excelencia Robótica’s da Vinci and Ion business are now owned by Intuitive. Business operations are integrated into Intuitive’s European commercial and marketing organization, headed by senior VP and GM Dirk Barten.

There is a combined installed base of more than 470 da Vinci surgical systems in Italy, Spain and Portugal as of December 31, 2025. The Ion endoluminal system was recently launched in Italy and Spain.

“Intuitive is entering a new chapter, building on more than two decades of introducing and scaling access to our technology across Southern Europe,” said Barten. “We are excited to welcome approximately 250 employees to the Intuitive team as we commence our direct operations, and together continue driving innovation in service of patients, care teams, and healthcare professionals.”

In January, Intuitive earned U.S. Food and Drug Administration (FDA) clearance of the da Vinci 5 robotic surgical system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization.